The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309289 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Shayeste Sadat Baghermanesh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Purines, MicroRNAs, Aminopyridines, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iran University of Medical Sciences.
Abstract (Originalsprache)
Introduction Patients with breast cancer, especially triple-negative breast cancer, have a poor prognosis. There is still no effective treatment for this disease. Due to resistance to traditional treatments such as chemotherapy and radiation therapy, there is a need to discover novel treatment strategies to treat this disease. Ribociclib is a selective CDK4/6 inhibitor. Approximately 20% of patients with HR+ breast cancer developed primary resistance to CDK4/6 inhibitors, and more than 30% experienced secondary resistance. Since most patients experience resistance during CDK4/6 inhibitor treatment, managing this disease is becoming more challenging. Many malignant tumors abnormally express microRNA (miR)-141, which participates in several cellular processes, including drug resistance, proliferation, epithelial–mesenchymal transition, migration, and invasion. Materials and methods In the present study, we cultured MDA-MB-231 and MCF-7 cells in DMEM-F12 medium. By performing MTT assay we determined the cytotoxic effects of ribociclib on breast cancer cells, as well as determining the IC50 of it. Then, we treated the cells with ribociclib at two time points: 24 h and 72 h. After that, RNA was isolated and reverse transcribed to cDNA. Finally, we performed qRT‒PCR to evaluate how ribociclib affects the expression level of desired genes. Results and conclusion We found that ribociclib can inhibit cell growth in a dose- and time-dependent manner. We examined the mRNA expression of 4 genes. After ribociclib treatment, the mRNA expression of CDK6 and MYH10 decreased (p < 0.01, p < 0.05). The mRNA expression of CDON increased (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Shayeste Sadat Baghermanesh, Mahmood Barati, Arshad Hosseini
Förderung
- Iran University of Medical Sciences
Zitieren
APA
Baghermanesh, S. S., Barati, M., & Hosseini, A. (2024). The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells. PLOS ONE. https://doi.org/10.1371/journal.pone.0309289
Vancouver
Baghermanesh SS, Barati M, Hosseini A. The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells. PLOS ONE. 2024. doi:10.1371/journal.pone.0309289
BibTeX
@article{Baghermanesh2024,
author = {Baghermanesh, Shayeste Sadat and Barati, Mahmood and Hosseini, Arshad},
title = {The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309289}
}
EUVIMED